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Abstract
Background
Traumatic coagulopathy is thought to increase mortality and its treatment to reduce pre-
ventable deaths. However, there is still uncertainty in this field, and available literature
results may have been overestimated.
Methods
We searched the MEDLINE database using the PubMed platform. We formulated four que-
ries investigating the prognostic weight of traumatic coagulopathy defined according to con-
ventional laboratory testing, and the effectiveness in reducing mortality of three different
treatments aimed at contrasting coagulopathy (high fresh frozen plasma/packed red blood
cells ratios, fibrinogen, and tranexamic acid administration). Randomized controlled trials
were selected along with observational studies that used a multivariable approach to adjust
for confounding. Strict criteria were adopted for quality assessment based on a two-step
approach. First, we rated quality of evidence according to the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) criteria. Then, this rating was
downgraded if other three criteria were not met: high reporting quality according to shared
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standards, absence of internal methodological and statistical issues not detailed by the
GRADE system, and absence of external validity issues.
Results
With few exceptions, the GRADE rating, reporting and methodological quality of observa-
tional studies was “very low”, with frequent external validity issues. The only two random-
ized trials retrieved were, instead, of high quality. Only weak evidence was found for a
relation between coagulopathy and mortality. Very weak evidence was found supporting
the use of fibrinogen administration to reduce mortality in trauma. On the other hand, we
found high evidence that the use of 1:1 vs. 1:2 high fresh frozen plasma/packed red blood
cells ratios failed to obtain a 12% mortality reduction. This does not exclude lower mortality
rates, which have not been investigated. The use of tranexamic acid in trauma was sup-
ported by “high” quality evidence according to the GRADE classification but was down-
graded to “moderate” for external validity issues.
Conclusions
Tranexamic acid is effective in reducing mortality in trauma. The other transfusion practices
we investigated have been inadequately studied in the literature, as well as the independent
association between mortality and coagulopathy measured with traditional laboratory test-
ing. Overall, in this field of research literature quality is poor.
Introduction
According to theWHO, trauma is one of the main causes of mortality worldwide with more
than 1.2 million deaths per year, and the first among young people. [1]. To avoid death from
hemorrhage in severely injured trauma patients, surgical or endovascular efforts to achieve
hemostasis should be performed as early as possible. These treatments have been combined
with transfusion algorithms supporting hemostasis. [2]. The attention of the scientific commu-
nity has particularly focused on acute traumatic coagulopathy (ATC) which has frequently
been recognized in severe trauma [3]. In different studies dealing with severe trauma using dif-
ferent and heterogeneous definitions of ATC, the prevalence of ATC ranges between 24 and
56% [4]. Treatment of coagulopathy is thought to reduce mortality in the severely bleeding
trauma patients, and different therapeutic approaches have been proposed such as high ratios
of fresh frozen plasma (FFP) and of platelets with packed red blood cells (PRBC), fibrinogen or
cryoprecipitate administration and the use of antifibrinolytic drugs. However, there is still
uncertainty on how to define coagulopathy and the efficacy of hemostatic algorithms [5, 6].
We therefore performed a systematic review and qualitative analysis based on strict methodo-
logical assessment of available literature, to verify the possibility of overoptimistic or unreliable
results that have become a serious issue in medical literature [7, 8].
In February 2015 in the context of the 10th edition of the Trauma Update and Organization
Conference held in Bologna (Italy), a meeting of experts was organized with the goal of screen-
ing scientific evidence regarding trauma related coagulopathy, administration of high FFP:
PRBC ratios, fibrinogen, and tranexamic acid, in severely injured patients. We report the
results of the systematic review of the literature performed to support the works.
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Methods
The Coordinating Committee, formed by intensivists, surgeons, emergency department physi-
cians, and experts in coagulation and transfusion practices generated the list of topics object of
the review.
Four queries were formulated, one investigating the effects of coagulopathy in trauma and
the other three focused on the effectiveness of different transfusion approaches. The four que-
ries were formulated as follows:
1. Does coagulopathy affect mortality in trauma?
2. Does a fixed blood to plasma transfusion ratio reduce mortality in trauma?
3. Does hypofibrinogenemia treatment reduce mortality in trauma?
4. Does tranexamic acid administration reduce mortality in trauma?
Literature Search Strategy
We searched the MEDLINE (using the PubMed platform) retrieving four lists of studies, one
for each query, according to search strategies reported in the supporting information.
Study selection. Four groups of physicians, one for each query, were selected to screen the
literature. Each group received the list of articles and performed the first selection on the basis of
titles and abstracts excluding those that did not deal with the subject at hand. We selected only
studies that included a study and a control group, including randomized controlled trials (RCTs)
and observational studies only if adjustment for confounders was performed (e.g. logistic regres-
sion, matching). We also includedmeta-analyses and reviews for manual evaluation of the bibli-
ography of the articles as a source of literature that may have escaped the PubMed search.We
did not include letters, case reports, and observational studies without controls and adjustment
for important covariates. Studies on children (age 16) were excluded.We excluded as well
studies focusing on specific conditions such as head bleeding, considering instead abdominal,
thoracic, pelvic bleeding, and coagulopathy in general.We excluded traumatic brain injury
because of the great prognostic weight carried by evenmodest bleeding and because the outcome
of choice in our review, mortality, is not suitable for traumatic brain injury studies for which a
composite outcome including death, vegetative status, and severe disability is preferable. For gen-
eralizability issues we excluded studies carried out in the military setting. Such studies have pro-
vided fundamental evidence for therapeutic strategies in the field of trauma, but substantial
differences in case-mix and health-care context hamper, in our opinion, the translation of evi-
dence to the civilian context. Bleeding or coagulopathy from other causes (as obstetrical or peri-
operative) were not considered. Finally, we applied English-language restriction.
Data analyses. Full texts of the selected articles were collected and submitted for detailed
methodological assessment by statistical experts (DP, AC).
Data extractionwas performed according to a predefined plan (the protocol was not pre-
registered), using a dedicated electronic form that automatically performed all planed compu-
tations and plot generation already tested in a previous reviewing process performed by the
Trauma Update review group [9].
We presented data as event rates in treatment arms and controls, absolute risks, absolute
risk reductions, and relative risks.We reportedmultivariate analysis results as adjusted odds or
hazard ratios. Numbers needed to treat were also calculatedwhen appropriate. We calculated
confidence intervals for all the above measures. Confidence intervals for the number needed to
treat include the area of numbers to treat for benefit (NNTB) and the area of numbers needed
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to treat to be harmed (NNTH), separated by an infinity value which corresponds to an absolute
risk difference of zero [10]. We represented absolute and relative risks from RCTs in Forest
plots.
Evidence grading. We ranked the evidence provided by RCTs and observational studies
according to the Grading of Recommendations Assessment, Development and Evaluation
(GRADE) criteria without providing any recommendation because it was not an objective of
this study. GRADE rates evidence quality on a four-level scale ranging from “high” to “very
low”, according to confidence that raters have on the estimates of the effect [11]. RCTs provide
default “high” quality that can be downgraded if bias or other limitations are present. Observa-
tional studies, instead, are initially rated as “low” quality but can be up- or downgraded
depending on specific features. Consistently with shared evidence, the GRADE rating system
considers crucial adequate control for confounding which implies that when a models purpose
is explanatory, at least most known prognostic factors should be measured and included in the
model [12–14].
Although GRADE rating has been developed for bodies of evidence, we applied its evidence
quality criteria first to single studies and proceededwith body evidence analysis only in a fur-
ther step. According to GRADE rating, “very low” quality indicates that the degree of the esti-
mate uncertainty of the documented effects is so high as to be compatible with substantially
different true effects (including absence of any effect).
We provided a further quality assessment based on statistics reporting (which was graded as
“partial” or “sufficient for quality assessment”) and methodological/statisticalquality (“low” or
“high”). Finally, we verified the existence of external validity issues (“yes” or “no”).
We combined studies in meta-analyses and used statistical approaches to investigate pres-
ence of asymmetry and potential publication only if heterogeneity did not advise against these
procedures [15].
In synthesis, we rated evidence quality according to GRADE only after having verified that
the studies complied with three additional criteria:
1. High quality reporting (rated “partial” or “sufficient for quality assessment”):
a. According to the Consolidated Standards of ReportingTrials (CONSORT) statement for
RCTs [16].
b. According to indications provided by literature for observational studies [17].
2. Absence of methodological and statistical flaws. Specifically:
a. Flaws in regard to RCTs, defined by the CONSORT recommendations.
b. Flaws which can affect observational studies, not detailed by the GRADE system such as:
Risk of overfitting when less than 10 outcomes per variable are available [18, 19]; bivari-
ate statistics tests used to screen variables for multivariable analysis [20]; abuse of auto-
matic variable selection procedures [21]; not accounting for immortal-time bias when
dealing with time-dependent treatments [22]; not balancing the probability of receiving a
specific treatment with propensity scores [23].
3. Absence of external validity issues, such as specificity of case-mix, of treatment protocols, of
health-care settings [5].
If these criteria were not met we downgraded the GRADE rating.
The reviewwas conducted complying with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) statement recommendations (S1 PRISMA Checklist)
[24].
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Results
Query # 1: Does coagulopathy affect mortality in trauma?
Out of 848 studies five were selected after application of exclusion criteria (Fig 1, Table 1, and
S1 File) [25–29]. Definition of coagulopathy was heterogeneous among studies: hypofibrino-
genemia, platelet reduction, increased activated partial thromboplastin time (APTT), pro-
thrombin time (PT), or international normalized ratio (INR). Inclusion criteria and case-mixes
were also different ranging from all patients with trauma [25] to those with trauma receiving
full trauma team activation (without any further specification) [26], to patients receiving differ-
ent number of packed red blood cells (PRBC) over different timespans [27, 28], to those with
low systolic blood pressure and not better specified “poor responsiveness to initial fluid resusci-
tation” [29].
In four studies statistical reporting concerningmultivariate analysis was inadequate (S1
File) [25, 27–29]. One of these studies dichotomized all the variables included in the model
without adequately justifying this approach and the cut-offs chosen [25]. Only one study had
fair reporting of statistics that appeared to be correctly performed [26]. This study, however,
provided a biphasic, paradoxical, independent effect of fibrinogen increase on mortality. It
turned out to strongly reduce mortality within low plasmatic levels, and to increase it at high
concentrations [26]. A similar paradoxical effect was observed for increasing values of the
injury severity score (ISS), with increased risk of death below the breakpoint of 25.7 and
reducedmortality for higher values [26]. This raises serious concerns on the adequacy of the
modeling process.
Three studies included only five variables in the mortality predictionmodels [27–29] and
important well-known prognostic factors were ignored such as age (omitted in one of the two
models developed in one study [28]), severity on admission (omitted in one study) [27], or
Glasgow coma scale (GCS) not included in two models [28, 29].
Another issue was result’s generalizability since only one study included a high number of
centers and patients (1,181) [28], a second one included four major trauma centers from three
different countries (1,133 patients included in the model) [26], a third one was carried out only
in two centers (517 patients) [29], and two were single center studies (7,638 and 331 patients,
respectively) [25, 27].
Conclusion: Because of heterogeneity in design and definition of coagulopathy, evidence
from different studies could not be combined as recommended by the GRADE working group.
Each single study provided “very low” evidence according to the GRADE rating system.
Statistical reporting was partial and the assessable statistical analyses were of “low” quality.
Only one study did not raise generalizability concerns.[28]
We, therefore, provided a conclusive “very low” rating to evidence quality.
Query # 2: Does a fixed blood-plasma transfusion ratio reduce mortality
in trauma?
We identified 1,288 studies, screened twenty-five full-texts, and after applying our exclusion
criteria we reviewed nine (Fig 2, Table 2, and S2 File) [27, 28, 30–36]. These nine studies were
quite heterogeneous in terms of treatment protocols, comparing several FFP/PRBC ratios, or
instead considering FFP/PRBC ratios as a continuous variable in multivariate analysis, or com-
paring patients that received or not FFP. Inclusion criteria were also quite different with one
study dealing only with ICU patients [31], one selecting patients on the basis of a severity score
value [33], two studies focusing on patients transfusedwith 10 or more PRBCwithin 24 hours
from admission [34, 35], and five based on other PRBC transfusion thresholds [27, 28, 30, 32,
Blood Component Therapy and Coagulopathy in Trauma
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36]. Study heterogeneity in terms of case-mix, treatment protocols, and outcome advised
against combination for overall evidence provision.
All but one study [36] did not develop a propensity score to account for the selection bias
associated with therapeutic choices.
Two studies adhering to the Trauma Registry-DeutscheGesellschaft für Unfallchirurgie
included about one hundred centers but, on average, only few patients per center, raising a
selection bias issue [32, 33]. On the other hand results from the four single center studies rea-
sonably may have had limited external validity [27, 31, 35, 36].
In general the statistical reporting was scanty and inadequate for quality evaluation. Impact
of FFP administration was also variable, with only six of eight studies showing a survival bene-
fit.[30, 32–35]
Compared to the others, the Prospective, Observational,Multicenter, Major Trauma Trans-
fusion (PROMMTT) study was of higher statistical quality since it accounted for immortal-
Fig 1. Query # 1: Does coagulopathy affect mortality in trauma? Studies selection flow diagram.
doi:10.1371/journal.pone.0164090.g001
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time bias and reported adequately the statistical design and results.[30] However, it was not
upgraded since in the face of a large effect it was probably underfitted for its explanatory pur-
pose and did not include a propensity score. Thus, it provided “low evidence” according to
GRADE, with adequate statistical reporting and quality, and no external validity issues.
The study reported a large and statistically significantmortality reduction in the first six
hours from admission, but no protective effect of high FFP/PRBC ratios (categorized on three
levels:< 1:2 as the reference, vs. 1:2—< 1:1, and vs. 1:1) between 6 and 24 hours, and 24
hours and 30 days.
Although, published after the conclusion of our literature search, we included in our analy-
sis a recent randomized controlled trial (RCT), the Pragmatic, RandomizedOptimal Platelet
and Plasma Ratios (PROPPR) trial (Table 3) [37]. This study recruited 680 severely injured
patients admitted to 12 level I trauma centers in the United States, randomizing patients to a
FFP/platelet/PRBC1:1:1 vs. 1:1:2 ratio. No statistically significant 28-hours mortality (12.8 and
17%, respectively) or 30-day mortality reduction was found (22.4 and 26.1%, respectively). The
reporting and the methodologywere adequate, so we gave a “high” quality rating according to
the GRADE criteria (S2 File).
The high-quality observational study [30] and the RCT [37] provided results that partially
converged on a common body of evidence. Both studies were carried out in level-1 trauma cen-
ters and included patients for whom the highest level of activation was required. Moreover,
high FFP/PRBC ratios 1:1 (or higher in the observational study) were compared with ratios 1:2
(or lower in the observational studies). Finally, overall 24-hour mortalities were similar in the
two groups (13.0% in the observational study and 14.8% in the RCT).
The observational study did not report an adjusted analysis based on cumulative mortality,
but indicated a very early (i.e. first six hour from admission) protective effect of high ratios,
and no protective effect in the 6-hour to 24-hour and 24-hour to 30-day models. The RCT con-
sidered instead cumulative 24-hour and 30-day mortalities. These results suggest that even if a
very early effectmay be present (“low evidence” provided by the observational study) in the
Table 1. Query # 1: Does coagulopathy affect mortality in trauma? Reporting of studies included in the revision. The number of patients is referred to
those included in the multivariable model. N = number, pts = patients, ctr = centre, OR = odds ratio, CI = confidence interval, APTT = activated partial throm-
boplastin time, PT = prothrombin time, INR = international normalized ratio.
First author—
Year
N of
pts
N of
centres
pts/
ctr/
year
Inclusion criteria Coagulopathy
indicated by
Outcome
Mortality
N (%)
Mortality OR (95%-CI)
Hagemo– 2014
[26]
1133 4 142 Patients initiating full trauma team
response, with time from injury to
arrival within 180 minutes
Fibrinogen and
platelet reduction,
INR increase
28-day
mortality: 99
(8.7)
Low fibrinogen 0.08 (0.03–
0.20). High fibrinogen 1.77
(0.94–3.32). INR 1.65 (0.65–
4.18). Platelet count 1 (1.0–
1.0).
Rourke– 2012
[29]
517 2 86 Patients who met criteria for local
trauma team activation, time from
injury to arrival within 120 minutes,
less than 2000 ml fluid administration
prior to hospital arrive
Fibrinogen reduction,
APTT increase
28-day
mortality: 62
(12)
Fibrinogen 0.22 (0.10–0.47).
APTT 1.05 (1.01–1.09).
Mitra– 2010
[27]
331 1 90 Patients receiving more than 4 packed
red blood cell units within 4 hours from
admission
INR increase,
Platelet count
reduction
30-day
mortality: 99
(29.9)
Platelet count 0.99 (0.99–
0.99). INR 1.43 (1.02–2.01).
MacLeod–
2003 [25]
7638 1 1272 All patients with trauma PT and APTT
increase
Hospital
mortality: NA
PT 1.35 (1.11–1.68). APTT
4.26 (3.23–5.62).
Sambavisan–
2011 [28]
1181 23 22 Patients receiving at least one but less
than 10 PRBC units within 24 hours
from admission
APTT increase Hospital
mortality: 173
(14.6)
APTT 1.015 (1.010–1.019).
doi:10.1371/journal.pone.0164090.t001
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medium and long period no beneficial effect is detected (“high evidence” mainly attributable to
the RCT).
Conclusion: Of the nine selected observational studies eight were downgraded to “very low”
according to the GRADE rating system. Further, they provided “partial” statistical reporting
Fig 2. Query # 2: Does a fixed blood-plasma transfusion ratio reduce mortality in trauma? Studies selection flow
diagram.
doi:10.1371/journal.pone.0164090.g002
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Table 2. Query # 2: Does a fixed blood-plasma transfusion ratio reduce mortality in trauma? Reporting of observational studies included in the revi-
sion. The number of patients is referred to those included in the multivariable model. N = number, pts = patients, ctr = centre, FFP = fresh frozen plasma,
PRBC = packed red blood cells, OR = odds ratio, HR = hazard ratio, CI = confidence interval, Cont. Var. indicates that variables are used as continuous in
the models, when not specified they have been categorized.
First author—
Year
N of
pts
N of
centres
pts/
ctr/
year
Inclusion criteria Outcome Mortality (%) Mortality OR (95%-CI)*
Scalea– 2008
[31]
NA 1 NA Patients admitted to the ICU for trauma
occurred within 24 hours
Hospital
mortality
NA PRBC:FFP ratio 1:1 0.57 (0.19–1.66).
PRBC:FFP ratio (Cont. Var.) 1.23
(0.81–1.87)
Inaba– 2010
[36]
568 1 95 Trauma admitted to surgical ICU
receiving < 10 PRBC units within 12
hours from admission (excluding deaths
occurred within 24 hours)
Hospital
mortality
89 (15.7) FFP 1.27 (0.81–2.0)
Wafaisade–
2011 [32]
1362 116 3 Patients survived one hour from
admission receiving more than 3 and
less than 10 PRBC units from arrival to
the ER and admission to the ICU
Hospital
mortality
321 (23.6) FFP:PRBC ratio <1:1 reference.
FFP:PRBC ratio = 1:1 0.8 (0.54–1.18)
FFP:PRBC ratio >1:1 0.52 (0.31–
0.87)
Holcomb– 2013
[30]
876 10 79 Trauma patients receiving at least 3
PRBC units within 24 hours from
admission
Hospital
mortality
NA FFP:PRBC ratio > = 1:1 HR 0.23
(95%-CI NA) FFP:PRBC ratio: 1:2
—<1:1 HR 0.42 (95%-CI NA) FFP:
PRBC ratio < 1:2 HR ref = 1 (95%-CI
NA) FFP:PRBC (Cont. Var.) HR 0.31
(0.16–0.58)
Teixeira– 2009
[35]
383 1 64 Trauma patients receiving 10 or more
PRBC units within the first 24 hours
Hospital
mortality
161 (42) FFP:PRBC ratio 0.02 (0.01–0.07)
Sambavisan–
2011 [28]
1181 23 22 Patients receiving at least one but less
than 10 PRBC units within 24 hours from
admission (excluding patients dies
within 2 hours from admission)
Hospital
mortality
173 (14.6) FFP:PRBC ratio1 HR 0.87 (0.55–
1.38)
Holcomb– 2011
[34]
643 22 29 Trauma patients receiving 10 or more
PRBC units within 24 hours from
admission
30-day
mortality
181 (28.1) FFP:PRBC ratio (Cont. Var.) HR 0.49
(0.28–0.86)
Borgman– 2011
[33]
557 100 1 TASH score 15 excluding patients
died within 1 hour from admission
Hospital
mortality
NA FFP:PRBC ratio (Cont. Var.) Survival
OR 2.5 (1.56–4.00)§
Mitra– 2010
[27]
331 1 90 Patients receiving more than 4 packed
red blood cell units within 4 hours from
admission
30-day
mortality
99 (29.9) FFP:PRBC ratio (Cont. Var.) 0.15
(0.05–0.48)
* When the chosen multivariable analysis is a proportional-hazards regression model, the result is preceded by the acronym “HR”, in all the other cases
ORs from logistic regression are implied.
§ In this case the survival and not the mortality OR was calculated.
doi:10.1371/journal.pone.0164090.t002
Table 3. Query # 2: Does a fixed blood-plasma transfusion ratio reduce mortality in trauma? Results of the Pragmatic, Randomized Optimal Platelet
and Plasma Ratios (PROPPR) trial [37]: 24-hour and 30-day mortality are reported. RR = relative risk, CI = confidence interval, NNTB = number needed to
treat for benefit, NNTH = number needed to treat to be harmed, FFP = fresh frozen plasma, PRBC = packed red blood cells.
Treatment Control Investigated
Outcome
% (95%-CI)
Treatment arm
% (95%-CI)
Controls
% (95%-CI)
Difference
RR (95%-CI) NNTB/NNTH
FFP/platelet/PRBC
Ratio 1:1:1–335
patients
FFP/platelet/
PRBC 1:1:2–341
patients
24-hours
mortality
12.8 (9.7 to 16.8) 17 (13.4 to
21.4)
-4.2 (-9.6 to
1.2)
0.75 (0.52 to
1.09)
NNTB 24 (95%-CI
NNTB 10 to1 to
NNTH 82)
FFP/platelet/PRBC
1:1:1–335 patients
FFP/platelet/
PRBC 1:1:2–341
patients
30-day mortality 22.4 (18.3 to
27.2)
26.1 (21.7 to
31)
-3.7 (-10.1 to
2.8)
0.86 (0.66 to
1.12)
NNTB 27 (95%-CI
NNTB 10 to1 to
NNTH 36)
doi:10.1371/journal.pone.0164090.t003
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and had “low” methodological quality, most having external validity limits. Our final evalua-
tion confirmed the “very low” GRADE rating.
We confirmed the “low” GRADE rating also for the PROMMTT study for which we did not
have generalizability, statistical reporting and quality concerns [30]. The PROPPR trial was a
well-conducted RCT with “high” evidence quality according to GRADE and confirmed in our
final evaluation [37].
The two studies were sufficiently homogeneous to provide cumulative “high” level evidence
against the greater efficacy of 1:1 vs. 1:2 FFP/RPBC ratios.
Query # 3: Does hypofibrinogenemia treatment reduce mortality in
trauma?
Of the 914 retrieved studies five were left for full-text screening, but only one matched our
inclusion criteria (Fig 3, Table 4, and S3 File) [29]. The study included patients with suspected
active hemorrhage, hypotension, and scarce response to fluid resuscitation (S3 File, Table 4).
Individual fibrinogen doses were calculated on the basis of FFP, platelet, and cryoprecipitate
that were administered. In the 28-day logistic regression model fibrinogen administration
within 12 hours (conditional on 12-hour survival) seemed to have a protective effect, the result
being barely not significant (OR 0.91; 95%-CI 0.81–1.01). The statistical reporting was however
too poor for a correct evaluation. The model included only five variables, did not include a pro-
pensity score for fibrinogen administration, and did not account for immortal-time bias.
Conclusion: Evidence from this study was rated “very low” according to the GRADE classi-
fication, statistical reporting was “partial” and quality of reported statistics was “low”, we raised
generalizability issues since only two centers participated to the study. Our final judgment con-
firmed the “very low” GRADE category.
Query # 4: Does tranexamic acid administration reduce mortality in
trauma?
The PubMed search provided 1,074 results, 25 studies were fitted the criteria for full-text
screening and 24 were discarded (Fig 4, Table 5, and S4 File). Only the 2010 CRASH-2 trial
was left for evidence provision [38]. This was a very large, multicenter, international trial
including trauma patients with systolic blood pressure lower than 90 mmHg and/or heart rate
higher than 110 beats per minute or who were considered at risk of significant hemorrhage.
Patients were randomized to receive either tranexamic acid or placebo within 8 hours from
injury. The reporting of statistics, design, and results was adequate and we rated study quality
as “high” according to the GRADE classification. Statistically significant 28-day mortality
reduction was found with a relative risk of 0.91 (95%-CI 0.85–0.97; p = 0.0035). Absolute mor-
tality reduction was 1.5% (95%-CI 0.5–2.5) from 16% for patients receiving placebo to 14.5%
in the treatment group, the number needed to treat for benefit being 68 (95%-CI 40–206).
Conclusion: Evidence provided by the study was rated “high” according to the GRADE clas-
sification, statistical reporting was adequate, and statistical quality was high. However, the
study was carried out mainly in developing countries raising an issue of generalizability to
Western countries health-care contexts. We thus downgraded to “moderate” the quality of evi-
dence in our final evaluation.
Discussion
Although a great number of articles dealing with coagulopathy and transfusion practices in
trauma have been published, only few in our revision were rated as having an acceptable
Blood Component Therapy and Coagulopathy in Trauma
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Fig 3. Query # 3: Does hypofibrinogenemia treatment reduce mortality in trauma? Studies selection flow diagram.
doi:10.1371/journal.pone.0164090.g003
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Table 4. Query # 3: Does hypofibrinogenemia treatment reduce mortality in trauma? Reporting of studies included in the revision. The number of
patients is referred to those included in the multivariable model. N = number, pts = patients, ctr = centre, OR = odds ratio, CI = confidence interval.
First
author—
Year
N of
pts
N of
centres
pts/ctr/
year
Inclusion criteria Outcome
Mortality (%)
Treatment OR (95%-CI)
Rourke–
2012 [29]
517 2 86 Time from injury to arrival within 120 minutes,
SBP < 90 at admission, poor responsiveness to
initial fluid administration
28-day
mortality 62
(12)
Fibrinogen administration
within the first 12 hours
Fibrinogen 0.91
(0.81–1.01).
doi:10.1371/journal.pone.0164090.t004
Fig 4. Query # 4: Does tranexamic acid administration reduce mortality in trauma? Studies selection flow diagram.
doi:10.1371/journal.pone.0164090.g004
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quality to be a reliable source of evidence.Moreover, heterogeneity in design, definitions, and
treatment protocols was high, hampering the combination of single study results in an unique
body of evidence, as recommended by the GRADE.
During the revision process, besides insufficient statistical reporting, we frequently encoun-
tered internal validity issues connected to the inappropriate use of multivariable models.
Besides technical flaws, such as low variable/outcome ratios or bivariate use for variables selec-
tion consistent with similar findings in other fields of research [17, 39–41], models were fre-
quently underfitted for their explanatory purposes [14]. This means that the number of
important predictors included in the models was insufficient to prove that the association
between variables (e.g. a specific treatment) and outcome was causal in nature, because of the
high risk of confounding. Underfitted models may exaggerate the quantitative relations
between specific variables and outcomes or even present spurious associations as causal.
Another weak point of most studies, was the small number of centers participating (many
studies were carried out in one or two centers), which may raise generalizability issues when
study centers have specific case-mix and health-care organization features [5].
Crucial for the aim of our study (i.e. grading the evidence in support of transfusion practices
in trauma, finalized at improving survival) was to define coagulopathy and assess its relation
with standardizedmortality as a prerequisite for understanding the potentials for treatment.
Literature review showed lack of agreement with regard to the definition of acute trauma coa-
gulopathy, which was heterogeneous across selected studies, thoughmainly based on hypofi-
brinogenemia or prolongation of PT or APTT, or INR increase over arbitrary cut-offs.
Unfortunately, the studies we scrutinized that investigated the independent association
between coagulopathy and death included few variables in their multivariable models, often
omitting important predictors, an inadequate approach when the purpose is explanatory (i.e.
the correct characterization of the relationship between independent variables and the out-
come) and not prognostic [14]. Although, a relation between coagulopathy and death is plausi-
ble and does not need any demonstration, to target specific treatments we should be able to
discriminate between patients that are dying because they are bleeding and those that are
bleeding as a terminal event of severe trauma.
Interestingly, the studies dealing with FFP/PRBC ratios adopted very heterogeneous inclu-
sion criteria, witnessing, in our opinion, the difficulty of researchers in defining the target pop-
ulation for treatment, generically focusing on patients with severe bleeding which includes a
large range of definitions. Severity was often not defined by clinical conditions but by therapy,
i.e. a high number of PRBC administered in a certain time frame, for example 24 hours. This
definition, however, generates a paradox because when translated into clinical practice it
requires the prediction on hospital admission of the amount of PRBC units a patient will
receive in the following hours to select those for whom the high FFP/PRBC ratio is indicated.
Physicians may discriminate reliably between extreme conditions, i.e. patients with very severe
bleeding on one hand and those with limited severity on the other, but probably not within
intermediate degrees of severity. Patients at high risk of dying for coagulopathy should be
Table 5. Query # 4: Does tranexamic acid administration reduce mortality in trauma? Results of the CRASH 2 trial [38]. The number of patients is
referred to those included in the multivariable model. CI = confidence interval, RR = relative risk, NNTB = number needed to treat for benefit.
Treatment Control Investigated
Outcome
Mortality rate in the
treatment arm %
(95%-CI)
Mortality rate in
controls %
(95%-CI)
% (95%-CI)
Difference
RR
(95%-CI)
NNTB/NNTH
Tranexamic acid—
10060 trauma
patients
Placebo—
10067 trauma
patients
28-day mortality 14.5 (13.9 to 15.2) 16 (15.3 to 16.8) -1.5 (-2.5 to
-0.5)
0.91 (0.85
to 0.97)
NNTB 68 (95%-
CI NNTB 40 to
NNTB 206)
doi:10.1371/journal.pone.0164090.t005
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instead spotted using variables collectable at admission. To develop an accurate predictive
model, however, permanent registries involving tenths of centers and thousands of patients are
needed, and a high number of variables for each patient need to be collected.Unfortunately,
the achievement of this goal seems currently out of sight.
Among the studies the PROMMTT had a high statistical quality, accounting for the immor-
tal-time bias [30]. This bias is attributable to the higher chance of receiving FFP transfusion
that patients who survive the first few hours after admission have. Thus, survival becomes the
condition to receive treatment and not the opposite. Treatment is thus a time-dependent vari-
able that should be modeled properly when using multivariable approaches. Modeling should
account for the fact that the timeframe between admission and treatment is a period of survival
(i.e. the immortal time) without exposure to treatment [22]. Unfortunately, this study did not
account for selection bias with a propensity score and was probably underfitted to account ade-
quately for confounding. This study analyzed separately the adjusted effect of high FFP/PRBC
ratios on mortality in the first 6 hours from admission, between 6 and 24 hours, and between
24 hours and 30 days. Treatment was effective only in the earliest period.However, early mor-
tality is not the best outcome when dealing with severely ill patients because it does not account
for late mortality related to the initial injury. This approach will not recognize potential initial
“cosmetic” effects which may avoid early deaths, but actually only delay the outcome.
Since there is no analysis focused on cumulative delayed mortality in the PROMMTT study,
its results should not be compared with those from the PROPPR trial that reported no statisti-
cally significant 24-hours and 30-day mortality reduction attributable to administration of 1:1
vs. 1:2 FFP/PRBC ratios. The RCT provides “high” evidence against a large protective effect
(12%mortality reduction assumed for sample size calculation in the RCT) of high FFP/PRBC
ratios. Such a large protective effect was probably an excessively ambitious goal of the PROPPR
study, not thoroughly compliant with the principle that the minimal clinically relevant differ-
ence (say, a 5%mortality reductions would have been a more than fair objective) should guide
sample size computation [42]. This means that though there is high evidence against the use of
1:1 ratios to obtain a 12%mortality reduction, there is no evidence that, say, a 5% mortality
reduction could or could not be achieved, and “absence of evidence is not evidence of absence”
[43].
Our results are in contrast with the evidence quality assessment provided by two recent
guidelines [44, 45]. Hunt et al. rated as “moderate” evidence quality (B grade according to the
GRADE classification) concerning 1:1 FFP:PRBC ratios in trauma, on the basis of achieved
hemostasis and exsanguination results from the PROPPR trial [44]. Unfortunately, the asses-
sors of these subjective endpoints were not blinded with regard to treatment assignment at that
point of the study, with a high risk of detection bias [5]. Mainly for the same reason Rossaint
et al. also rated as “moderate”, evidence in favor of FFP:PRBC ratios 1:2 for the treatment of
severely bleeding trauma patients [45]. The rating attributed to evidence in support of high
FFP:PRBC ratios was excessively optimistic in our opinion, since the PROPPR trial failed to
demonstrate any survival advantage (the primary outcome of the study) and the remaining lit-
erature mostly provided insufficient evidence.
We only selected one study dealing with tranexamic acid administration, which was the
only RCT performed in this field [38]. The study was correctly designed and performed, and
was provided with a high evidence level. We however have doubts on its generalizability to
Western countries, since most patients were enrolled in developing countries with very differ-
ent health-care systems. We hypothesized, for example, that time from trauma to surgery
could be prolonged in some of these countries. In this case the contrast of fibrinolysis could
prolong survival time increasing the chance of receiving surgical hemostasis. This beneficial
effect could be less relevant (the study demonstrated a 1.5%mortality reduction) when surgical
Blood Component Therapy and Coagulopathy in Trauma
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hemostasis is timely. In the CRASH 2 trial about half the sample did not receive any blood
product. It is likely that a minority of patients died early preventing any transfusion treatment
but that most were at very low risk of death. The use of broad inclusion criteria in this study
may have diluted the results of the study, which showed only a 1.5% 28-day mortality reduc-
tion.We may reasonably hypothesize that a significantly greater impact would have observed
in cases severe hemorrhage.
Finally, no evidencewas found in support of fibrinogen administration in the bleeding trau-
matic patient, since the only selected study bore paradoxical results [29]. Moreover, fibrinogen
was administered as FFP, platelets, and cryoprecipitate. FFP contains other coagulation factors
besides fibrinogen and requires high volume administration determining hemodilution. Thus,
it is probably not the best choice when the objective is to compensate fibrinogen consumption.
In this case too our evaluation was discordant with that of recent European guidelines [45],
which attribute a C grade level of evidence, basing their evaluation of fibrinogen administration
efficacyon a single study carried out in a combat setting, which did not account for the immor-
tal-time bias, did not use a propensity score, and adopted a clearly underfittedmodel with only
three variables [46].
On the other hand, the use of fibrinogen in clinical practice which is spreading in cases of
massive hemorrhages is based on solid theoretical basis, and, therefore, should not be aban-
doned solely because it has been inadequately studied, again consistently with the principle
that “absence of evidence is not evidence of absence” [43].
Study limitations
The main limit of our reviewwas that, due to limited resources, we only searched the MED-
LINE database using the free PubMed provider. We also applied very strict methodological cri-
teria, which made our analysis sensitive but may have ended up excluding articles potentially
valuable for the study of coagulopathy in trauma.
Conclusions
Tranexamic acid is effective in reducing mortality in trauma. High 1:1 FFP/PRBC ratios are
not effective in determining a 12%mortality reduction compared to 1:2 ratios. Fibrinogen
administration in trauma has not been studied adequately, and its effectiveness, supported by a
strong theoretical rational, cannot be excluded. The definition and prognostic role of traumatic
coagulopathy has been insufficiently addressed by current literature.
The difficulty to perform trials in the field is witnessed by the fact that in our reviewwe
retrieved only two RCTs. A large amount of observational studies, instead, have been carried
out in this field but only few were of sufficient quality. Nevertheless, observational studies still
appear to be the most feasible solution for evidence gathering in this field. Our suggestions for
future observational studies are summarized in S5 File.
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